Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Novo Nordisk has acquired the global rights to United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn.

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Second, one of Novo Nordisk's leading pipeline candidates failed to knock things out of the park. The company is developing CagriSema as a weight management medicine. In December, Novo Nordisk ...

Novo Nordisk produces most of their drugs in Europe, which could make them subject to tariffs and margin pressures. Also, Cagrisema, their drug in Phase 2 development, achieved 22.7% of weight ...

Indeed, the stakes are high. Novo Nordisk recently suffered a setback with CagriSema, its next-generation injectable drug in testing to treat both obesity and type 2 diabetes. The drug hit its ...